Vertis raises $37 million in venture financing:
This article was originally published in Clinica
Vertis Neuroscience, which develops devices for treating diseases and disorders of the nervous system, has closed a $37 million round of venture financing. The Seattle-based company has developed the Vertis PNT, a minimally invasive, nonsurgical treatment for low back pain through the delivery of electrical stimulation to the deep tissues near the spine. The product received FDA clearance in December 2001. Proceeds from the financing will be used to support sales and marketing of the product. The new investors include Johnson & Johnson Development, J&J's venture capital company.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.